RedHill Biopharma Ltd. (RDHL) Announces Positive Preliminary Pre-Clinical Data With RHB-104 For The Treatment Of Type 1 Diabetes
6/26/2014 7:19:18 AM
TEL-AVIV, Israel, June 26, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer, today announced preliminary positive data from a pre-clinical study with RHB-104 for the treatment of type 1 diabetes, a chronic autoimmune disease with an unknown cause. In light of the preliminary positive data, and subject to the final results and an independent report expected in the coming weeks, the Company is currently assessing the next steps in the development program, including a possible Phase II proof of concept clinical study for type 1 diabetes.
Help employers find you! Check out all the jobs and post your resume.
comments powered by